Crucell and DSM Announce Licensing and Service Agreement with Roche for Protein Production
Roche has selected PER.C6® for this particular protein because it believes PER.C6® possesses unique features capable of delivering the appropriate product quality. Further to this agreement, Crucell will work with Roche in creating a production clone for the specific protein.
Under the terms of the agreement, Roche will pay a research license payment, annual maintenance fees, and research funding. Further financial details were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.